Name

Singular Genomics

Legal name

Singular Genomics Systems, Inc.

Website

https://singulargenomics.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Genomics and Spatial Multiomics Instruments

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Single-Cell & Spatial Omics Services (HLAGANAC)

akta.pro secondary industries

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Spatial multiomics platforms
• Next-generation sequencing instruments
• In situ transcriptomics
• FFPE tissue analysis
• Genomic research reagents

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. G4X Spatial Sequencer Instruments: Sale of the G4X Spatial Sequencer instrument to research institutions, academic medical centers, and biopharma. Instrument sold with 12-month initial support services included.
2. Consumables and Reagents: Proprietary reagents, kits, and tools designed for use with the G4X instrument including spatial transcriptomics kits, multiomics kits, and custom panels. Consumables are single-use and must be repurchased for each run.
3. Product Services and Support: Support services including on-site support, software and instrument support, preventative maintenance, and validation. Initial 12-month support included with instrument purchase; extended warranty and service plans available for purchase.
4. Professional Services: Custom content design services and professional services for sample processing and data analysis. Custom G4X Panels designed to target customer-specified molecules.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Singular Genomics develops and sells the G4X Spatial Sequencer, a high-throughput in situ multiomics platform that performs simultaneous spatial transcriptomics (up to 1,300-plex RNA), 18-plex proteomics, and morphological (fH&E) analysis on a single FFPE tissue section at subcellular resolution, processing up to 128 samples per run. The company also sells the G4 benchtop next-generation sequencing platform plus proprietary consumables (spatial kits, RNA/protein panels, Direct-Seq reagents, TissuStamp tooling) and Spatial Services for technology access and support, targeting academic medical centers, research institutions, and biopharmaceutical customers.

Product overview

Singular Genomics offers a platform-plus-modules architecture centered on two core products: the G4X Spatial Sequencer and the G4 Sequencing Platform. The G4X is a high-throughput spatial multiomics platform that delivers simultaneous RNA, protein, and morphology analysis from FFPE tissue samples, while the G4 is a benchtop NGS sequencer for traditional sequencing workflows. The portfolio includes supporting kits (X2/X4 Spatial Transcriptomics and Multiomics Kits), consumables (RNA and Protein Panels), library prep adapters and primers, Direct-Seq in situ sequencing modules, TissuStamp tooling, and Spatial Services. The products share a unified ecosystem designed for translational research, clinical applications, and large-scale spatial biology studies.

Differentiator

Problem solved

Functional benefit

Products and services

• G4X Spatial Sequencer High-throughput in situ spatial multiomics platform that performs simultaneous RNA, protein, and fH&E morphological analysis on a single FFPE tissue section at subcellular resolution; processes up to 128 samples per run with approximately 40 cm² of imaging area. Sold to academic medical centers, research institutions, and biopharma customers in the United States, with 12-month initial support bundled.
• G4 Sequencing Platform Benchtop next-generation sequencer providing fast and accurate NGS results, compatible with a wide range of third-party library preparation products (10x Genomics, Agilent, IDT, NEB, Roche, etc.) through SG Universal Library Prep Adapter and SG UDI Primers.
• Spatial Services Professional services offering technology access programs, training, and support for the G4X platform, enabling researchers to generate multiomic data without instrument purchase; also includes custom panel design and sample/data analysis services for translational and clinical applications.
• X2 and X4 Spatial Transcriptomics Kit Proprietary spatial transcriptomics kit for gene expression profiling with spatial context, part of the spatial multiomics workflow on the G4 and G4X platforms; consumable requiring repurchase for each run.
• X2 and X4 Spatial Multiomics Kit Proprietary spatial multiomics kit enabling simultaneous profiling of RNA and protein from tissue samples with spatial resolution on the G4 and G4X platforms; consumable requiring repurchase for each run.
• RNA Panels for G4X Targeted RNA panels for the G4X platform including tissue-specific panels (lung, kidney, colon, breast) with immune-oncology focus, available in plex levels up to 1,300 genes for use with the G4X Spatial Sequencer.
• Protein Panels for G4X Multiplexed protein detection panels for the G4X platform enabling simultaneous protein expression analysis alongside RNA profiling on the same FFPE section.
• Direct-Seq In Situ Sequencing In situ sequencing technology enabling sequencing of variable regions within cells in FFPE tissue, supporting T- and B-cell receptor (immune repertoire) sequencing and somatic mutation profiling at subcellular resolution; Early Access planned for H2 2026.

Quantifiable outcome

• Nearly 20,000 FFPE samples processed and approximately 4 billion spatially resolved single cells profiled across dozens of sample types
• +3 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration16 records

Feature5 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• Vanderbilt University Medical CenterflagshipStrategic or Co-development Partner · 18 March 2026Center of Excellence collaboration deploying G4X Spatial Sequencer in support of HTAN's Pre-Gastric Cancer program (GAME3D). Aims to enable scalable, cost-efficient spatial multimodal profiling for building comprehensive 3D atlases of gastric disease progression from precancerous lesions to malignancy. G4X provides integrated in situ readouts combining 1,000-plex RNA, 18-plex protein, and fH&E at subcellular resolution.
• Beth Israel Deaconess Medical Center (Spatial Technologies Unit)flagshipStrategic or Co-development Partner · 12 March 2026Designation of Spatial Technologies Unit (STU) at BIDMC as G4X Center of Excellence. STU is first G4X Early Access Program site and a DF/HCC Core Facility. Partnership will share best-practice workflows from tissue preparation to data QC, study design, and downstream analysis to help researchers run reproducible G4X studies at scale.
• Tecan Group AGcoreTechnology or Integration · 1 July 2025Collaboration announced July 2025 to develop customized NGS reagent kits. Partnership aims to enhance automation in genomics workflows amidst rising US demand for diagnostics and personalized medicine. Tecan is a Swiss lab automation leader.
• Weill Cornell MedicinecoreStrategic or Co-development PartnerSPOT-Met (Spatial Predictors Of Tropism and Metastasis) initiative - a 1,000-tumor colorectal cancer program described as perhaps the world's largest colorectal cancer spatial multiomics initiative. Will leverage G4X platform for spatial multiomics profiling linking spatial readouts to clinical and molecular annotation to advance understanding of metastatic behavior.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Resolve Biosciences: Developer of the Molecular Cartography platform for subcellular spatial multiomics. Direct competitor in high-plex in situ spatial analysis; notably, current Singular CEO John Stark previously led Resolve Biosciences, indicating close technology and customer overlap.
• 10x Genomics: Direct competitor in spatial transcriptomics and in situ analysis, offering Visium, Visium HD, and Xenium platforms. Most well-funded and commercially scaled rival; comparable target customers (AMCs, biopharma) and similar spatial biology value proposition.
• Akoya Biosciences: Provider of the PhenoCycler (formerly CODEX) spatial proteomics platform and Opal multiplexed imaging reagents. Competes in the spatial biology market with a proteomics-led offering rather than transcriptomics, but addresses the same translational research and biopharma biomarker customers.
• Vizgen: Developer of the MERFISH-based spatial transcriptomics platform. Closely comparable technology (in situ spatial transcriptomics with subcellular resolution), targeting similar academic and translational research customers.
• Bruker (NanoString spatial business): Acquired NanoString's spatial biology assets including GeoMx digital spatial profiling and CosMx spatial molecular imager. Direct competitor in spatial multiomics with overlapping AMC and translational research customers.

Emerging players

• Bio-Techne: Provider of RNAscope in situ hybridization assays and the recently launched Advanced Cell Diagnostics spatial products. Comparable in the spatial transcriptomics reagent market and shares academic and translational research customers.
• RareCyte: Developer of the Orion spatial biology platform combining cyclic immunofluorescence with RNA in situ hybridization. Emerging competitor in the spatial multiomics space targeting similar AMC and translational customers.
• Element Biosciences: Developer of the AVITI benchtop NGS sequencer competing with Singular's G4 platform in the broader next-generation sequencing market. Less direct overlap on spatial multiomics but competes on the same sequencing-instrument purchase decisions.

Broad incumbents

• Illumina: Largest incumbent in next-generation sequencing with NovaSeq, NextSeq, and MiSeq platforms. Competes indirectly through sequencing customers who may default to Illumina for spatial workflows rather than adopting the G4 benchtop sequencer.

Others

• Tecan: Swiss lab automation leader partnering with Singular Genomics (July 2025) to develop customized NGS reagent kits. Comparable as an adjacent automation partner for genomics workflows and potential competitor in workflow integration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SingularGenomic
• LinkedInlinkedin.com/company/singular-genomics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Singular Genomics